Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Operating Leases (2023 - 2025)

Compass Therapeutics' Operating Leases history spans 3 years, with the latest figure at $8.8 million for Q4 2025.

  • For Q4 2025, Operating Leases rose 40.23% year-over-year to $8.8 million; the TTM value through Dec 2025 reached $8.8 million, up 40.23%, while the annual FY2025 figure was $8.8 million, 40.23% up from the prior year.
  • Operating Leases for Q4 2025 was $8.8 million at Compass Therapeutics, roughly flat from $8.8 million in the prior quarter.
  • Across five years, Operating Leases topped out at $9.6 million in Q2 2025 and bottomed at $536000.0 in Q4 2023.
  • The 3-year median for Operating Leases is $6.3 million (2025), against an average of $4.7 million.
  • The largest YoY upside for Operating Leases was 1074.63% in 2024 against a maximum downside of 7.04% in 2024.
  • A 3-year view of Operating Leases shows it stood at $536000.0 in 2023, then surged by 1074.63% to $6.3 million in 2024, then soared by 40.23% to $8.8 million in 2025.
  • Per Business Quant, the three most recent readings for CMPX's Operating Leases are $8.8 million (Q4 2025), $8.8 million (Q3 2025), and $9.6 million (Q2 2025).